Journals / Sağlık Hizmetleri ve Eğitimi Dergisi / 2021 / Cilt: 5 - Sayı: 2

Investigation of Gene Polymorphisms of Vaspin, Visfatin and Chemerin in Diabetic Obese and Non-Diabetic Obese Patients.

Pages
33–38
Publication Date
2021-09-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our results indicate that Chemerin rs17173608 and Visfatin rs2110385 gene polymorphisms were not risk factors for development of diabetes in obese individuals, however, Vaspin rs2236242 gene polymorphism may be a contributory risk of development of diabetes in obese individuals.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Diabetes mellitus and obesity are very similar in terms of pathogenesis and pathophysiology.
📊
Key Findings & Data:The study consists of 43 non-diabetic obese and 51 diabetic obese individuals.
💡
Conclusion & Impact:Our results indicate that Chemerin rs17173608 and Visfatin rs2110385 gene polymorphisms were not risk factors for development of diabetes in obese individuals, however, Vaspin rs2236242 gene polymorphism may be a contributory risk of development of diabetes in obese individuals.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Diabetes · Obesity · Vaspin

Abstract

Diabetes mellitus and obesity are very similar in terms of pathogenesis and pathophysiology. Most obese patients have adipose tissue dysfunction caused by genetic and environmental factors. Adipose tissue is the source of adipokines secreted from adipocytes. Vaspin, Visfatin and Chemerin are adipokines discovered in recent years. The study consists of 43 non-diabetic obese and 51 diabetic obese individuals. The PCR-RFLP method and agarose gel electrophoresis techniques were used to detect gene polymorphisms of Chemerin rs17173608, Vaspin rs2236242 and Visfatin rs2110385 from DNA samples. In our study, when diabetic obese and non-diabetic obese patient groups were examined in terms of Vaspin gene polymorphism, statistically significant results were obtained (22% → 7%, p=0.048, respectively). The distribution of Chemerin or Visfatin gene variants were not different in study groups (p>0.05). Our results indicate that Chemerin rs17173608 and Visfatin rs2110385 gene polymorphisms were not risk factors for development of diabetes in obese individuals, however, Vaspin rs2236242 gene polymorphism may be a contributory risk of development of diabetes in obese individuals.

🔖

Cite This Article

ORAN, K., GHEYBİ, A., ÇELİK, F., DURAK, Ş., DOĞAN, Z., AKSOYER, B., BAŞARAN, C., FAZLIOGULLARI, O., ÇETİNER, N. G., ZEYBEK, Ü. (2021). Investigation of Gene Polymorphisms of Vaspin, Visfatin and Chemerin in Diabetic Obese and Non-Diabetic Obese Patients.. Sağlık Hizmetleri ve Eğitimi Dergisi, Cilt: 5 - Sayı: 2, 33–38. https://ajindex.com/articles/798704

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. “Obesity and Overweight.” n.d. Accessed February 17, 2021. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Türkiye’de Obezitenin Görülme Sıklığı. n.d. Accessed February 17, 2021. https://hsgm.saglik.gov.tr/tr/obezite/turkiyede-obezitenin-gorulme-sikligi.html.
  2. Malik VS, Willett WC, and Hu FB. Global obesity: trends, risk factors and policy implications. Nature Reviews Endocrinology 2013.
  3. Bruce R, Godsland IC, Walton C, Crook D, Wynn W. Associations between insulin sensitivity, and free fatty acid and triglyceride metabolism independent of uncomplicated obesity. Metabolism 1994; 43(10):1275–81. Petersen KF and Shulman GI. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. American Journal of Cardiology 2002; 90 (5 Suppl.): 11–18.
  4. Lago F, Dieguez C, Gómez-Reino J and Gualillo O. Adipokines as emerging mediators of immune response and inflammation. Nature Clinical Practice Rheumatology 2007
  5. Zorena K, Duda OJ, Ślęzak D, Robakowska M and Mrugacz M. Adipokines and obesity. potential link to metabolic disorders and chronic complications. International Journal of Molecular Sciences 2020; 21 (10): 3570. Pang SS and Le Y. Role of resistin in inflammation and inflammation-related diseases. Cell Mol Immunol 2006;3:29–34.
  6. Yu Z, Han S, Cao X, Zhu C, Wang X, and Guo X. Genetic polymorphisms in adipokine genes and the risk of obesity: a systematic review and meta-analysis. Obesity 2012; 20 (2): 396–406. Steppan CM and Lazar MA. 2004. The current biology of resistin. Journal of Internal Medicine 2004; 255 (4):439–47. Pihlajamäki J, Ylinen M, Karhapää P, Vauhkonen I and Laakso M. The effect of the − 308a allele of the tnf -α gene on insulin action is dependent on obesity. Obesity Research 2003; 11(7):912–17. Dimova R and Tankova T. The role of vaspin in the development of metabolic and glucose tolerance disorders and atherosclerosis. BioMed Research International. Hindawi Limited 2015.
  7. Antje K, Kratzsch J and Kiess W. Adipocytokines: leptin - the classical, resistin - the controversical, adiponectin - the promising, and more to come. Best Practice and Research: Clinical Endocrinology and Metabolism. Baillière Tindall 2005.
  8. Colhoun HM, McKeigue MP and Smith GD. Problems of reporting genetic associations with complex outcomes. Lancet. Elsevier Limited 2003. Pearson TA and Manolio TA. How to interpret a genome-wide association study. JAMA - Journal of the American Medical Association 2008; 299 (11): 1335–44. Miller S. A simp